Glenn Michelson

A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors

Debashis Sarker, R. Molife, T. R. J. Evans et al. · Clinical Cancer Research · 2008 · 137 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

A Phase 2 Study of Rituximab in Combination with Recombinant Interleukin-2 for Rituximab-Refractory Indolent Non-Hodgkin's Lymphoma

Khuda Dad Khan, Christos Emmanouilides, Don M. Benson et al. · Clinical Cancer Research · 2006 · 102 citations · Full text

Medicine, Immunology, Pharmacology +15

Phase IIa Trial of Trastuzumab Emtansine With Pertuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive, Locally Advanced, or Metastatic Breast Cancer

Kathy D. Miller, Véronique Dièras, Nadia Harbeck et al. · Journal of Clinical Oncology · 2014 · 85 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia

Jeffrey E. Lancet, Farhad Ravandi, Rebecca M. Ricklis et al. · Leukemia · 2011 · 44 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors

Andrew J. Wagner, Paul Severson, Anthony F. Shields et al. · JAMA Oncology · 2021 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17